Eric Pauwels, Chief Business Officer of PTC Therapeutics Inc (NASDAQ:PTCT), executed a sale of 3,634 shares in the company on January 9, 2024, according to a recent SEC Filing. The transaction was carried out at an average price of $28.85 per share, resulting in a total value of $104,840.90.
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.
Over the past year, the insider has sold a total of 22,352 shares of PTC Therapeutics Inc and has not made any purchases of the stock. This latest transaction continues a pattern of sales by the insider, with no recorded buys over the same period.
The insider transaction history for PTC Therapeutics Inc shows a trend of more insider sales than buys over the past year. There has been only 1 insider buy, contrasted with 34 insider sells during the same timeframe.
On the valuation front, PTC Therapeutics Inc's shares were trading at $28.85 on the day of the insider's recent transaction. The company has a market capitalization of $2.171 billion.
The stock's price-to-GF-Value ratio stands at 0.42, with a GuruFocus Value of $68.34, indicating that PTC Therapeutics Inc is currently categorized as a Possible Value Trap, Think Twice according to its GF Value.
The GF Value is an intrinsic value estimate that takes into account historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
